title: A phase I evaluation of chronotropic delivery of floxuridine by hepatic arterial infusion in patients with metastatic colorectal cancer.
abstract: Hepatic arterial infusion (HAI) of floxuridine is often used for metastatic colorectal cancer, though this is associated with dose-limiting hepatobiliary toxicity. A phase I trial was initiated to determine if circadian-patterned HAI floxuridine would reduce toxicity. Twenty-one patients were enrolled, and they received a continuous 14-day HAI of floxuridine, with 90-95% of the drug delivered over the same six-hour period daily. The therapy was tolerable, but there was no reduction in hepatobiliary toxicity. The response rate of 33% (1 complete and 6 partial responses) was similar to that of regimens that do not utilize circadian timing. HAI floxuridine chronotherapy for metastatic colorectal cancer cannot be recommended.
authors: UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT GASTROINTESTINAL ONCOL & DIGEST DIS,DIV MED,HOUSTON,TX 77030. UNIV TEXAS,MD ANDERSON CANCER CTR,DIV PHARM,HOUSTON,TX 77030. UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT SURG ONCOL,DIV SURG & ANESTHESIOL,HOUSTON,TX 77030.
authors: D
authors: D
authors: Jones
authors: J
authors: J
authors: Chase
authors: M
authors: M
authors: Roh
authors: D
authors: D
authors: Hohn
authors: S
authors: S
authors: Curley
authors: R
authors: R
authors: Smith
authors: A
authors: A
authors: Hoque
authors: Y
authors: Y
authors: Patt